290 related articles for article (PubMed ID: 26228486)
21. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).
Didona B; Benucci R; Amerio P; Canzona F; Rienzo O; Cavalieri R
Br J Dermatol; 2004 Jun; 150(6):1198-201. PubMed ID: 15214911
[TBL] [Abstract][Full Text] [Related]
22. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
23. The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Rook AH; Zaki MH; Wysocka M; Wood GS; Duvic M; Showe LC; Foss F; Shapiro M; Kuzel TM; Olsen EA; Vonderheid EC; Laliberte R; Sherman ML
Ann N Y Acad Sci; 2001 Sep; 941():177-84. PubMed ID: 11594571
[TBL] [Abstract][Full Text] [Related]
24. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
Kempf W; Kettelhack N; Duvic M; Burg G
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
[TBL] [Abstract][Full Text] [Related]
25. Primary cutaneous T cell lymphomas: photochemotherapy immunomodulation with analysis of the inflammatory-expansive cellular dynamic.
Werber-Bandeira L; Herdy AM; Pagani EA; Filgueira AL
Dermatol Ther; 2014; 27(2):74-8. PubMed ID: 24703262
[TBL] [Abstract][Full Text] [Related]
26. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
27. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous intravascular NK/T-cell lymphoma.
Wang J; Yang X; Song Z; You Y
Australas J Dermatol; 2020 Feb; 61(1):61-63. PubMed ID: 31372987
[No Abstract] [Full Text] [Related]
29. Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure.
Del Guzzo CA; Kojadinovic A; Vinnakota RR; Geskin LJ; Newman JC; Langhoff E; Park YA; Bates SE; Dana AN
Oncologist; 2021 Sep; 26(9):727-e1488. PubMed ID: 33851477
[TBL] [Abstract][Full Text] [Related]
30. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
31. Emerging drugs in cutaneous T-cell lymphomas.
Dummer R
Expert Opin Emerg Drugs; 2005 May; 10(2):381-92. PubMed ID: 15934873
[TBL] [Abstract][Full Text] [Related]
32. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma.
Saven A; Carrera CJ; Carson DA; Beutler E; Piro LD
Blood; 1992 Aug; 80(3):587-92. PubMed ID: 1353380
[TBL] [Abstract][Full Text] [Related]
33. New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ
Curr Opin Oncol; 2016 Sep; 28(5):384-9. PubMed ID: 27390044
[TBL] [Abstract][Full Text] [Related]
34. The life cycle of cutaneous T cell lymphoma reveals opportunities for targeted drug therapy.
Berger CL; Edelson R
Curr Cancer Drug Targets; 2004 Nov; 4(7):609-19. PubMed ID: 15578918
[TBL] [Abstract][Full Text] [Related]
35. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.
Wysocka M; Newton S; Benoit BM; Introcaso C; Hancock AS; Chehimi J; Richardson SK; Gelfand JM; Montaner LJ; Rook AH
Clin Lymphoma Myeloma; 2007 Sep; 7(8):524-34. PubMed ID: 18021470
[TBL] [Abstract][Full Text] [Related]
36. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma.
Lindahl LM; Willerslev-Olsen A; Gjerdrum LMR; Nielsen PR; Blümel E; Rittig AH; Celis P; Herpers B; Becker JC; Stausbøl-Grøn B; Wasik MA; Gluud M; Fredholm S; Buus TB; Johansen C; Nastasi C; Peiffer L; Kubat L; Bzorek M; Eriksen JO; Krejsgaard T; Bonefeld CM; Geisler C; Mustelin T; Langhoff E; Givskov M; Woetmann A; Kilian M; Litman T; Iversen L; Odum N
Blood; 2019 Sep; 134(13):1072-1083. PubMed ID: 31331920
[TBL] [Abstract][Full Text] [Related]
37. Topical imiquimod therapy for cutaneous T-cell lymphoma.
Do JH; McLaughlin SS; Gaspari AA
Skinmed; 2003; 2(5):316-8. PubMed ID: 14673267
[No Abstract] [Full Text] [Related]
38. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
39. Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a.
Springer EA; Kuzel TM; Variakojis D; Kaul K; Rosen ST; Roenigk HH
J Am Acad Dermatol; 1993 Jul; 29(1):42-6. PubMed ID: 7686188
[TBL] [Abstract][Full Text] [Related]
40. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.
Szeimies RM; Bichel J; Ortonne JP; Stockfleth E; Lee J; Meng TC
Br J Dermatol; 2008 Jul; 159(1):205-10. PubMed ID: 18476957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
